Kornimate/medical-research-clean huggingface dataset:
research study investigating how well ndec works in people with sickle cell disease

Conditions: Sickle Cell Disease

Summary: this study examines how well a new, potential medicine called ndec works and is tolerated in people with sickle cell disease. ndec is a combination of two medicines (decitabine-tetrahydrouridine). both medicines are new for the treatment of sickle cell disease. participants who are not taking hydroxyurea (hu) will get ndec, ndec and placebo, or placebo. participants who are on hu treatment before joining the study will get ndec, ndec and placebo, or continue on hu. which treatment participants get is decided by chance. participants getting ndec and/or placebo will get capsules to take twice weekly. the study will last for about a year.


Eligibility criteria:
inclusion criteria: * age above or equal to 18 years at the time of signing informed consent * confirmed diagnosis of scd (including hbss, hbsc, hbsβ0 thalassaemia and hbsβ+ thalassaemia or other sickle cell disease variants) * 2-10 episodes of documented vaso-occlusive crisis (vocs) within the last 12 months prior to the screening visit * haemoglobin greater than or equal to 5.0 g/dl and below or equal to 10.5 g/dl at visit 1 * absolute reticulocyte count above upper limit of the normal (uln) at visit 1 * body weight 40 to 125 kg (inclusive). exclusion criteria: * patient is on chronic transfusion therapy as defined by receiving scheduled (pre-planned) series of blood transfusion (simple or exchange) for prophylactic purposes, or the patient is likely to begin chronic transfusion therapy during the course of the trial, or has received rbc or whole blood transfusion for any reason within 28 days of visit 1 * receipt of erythropoietin or other haematopoietic growth factor treatment within 28 days of signing icf, or planned treatment with these agents during the trial * receipt of voxelotor, crizanlizumab or l-glutamine treatment within 12 weeks of signing the informed consent form, or planned treatment with such agents during the trial * platelet count greater than 800 x 10\^9/l at visit 1 * absolute neutrophil count below or equal to 1.5 x 10\^9/l at visit 1 * any condition/concurrent chronic disease involving the stomach or small intestine which may affect drug absorption, as per investigator's judgement * female who is * pregnant, breast-feeding or intends to become pregnant within 6 months after the final trial product administration * child-bearing potential and not using highly effective methods of contraception and whose male partner is not using effective contraception, at screening and until 6 months after the last dose of trial product * male with female partner of childbearing potential who does not agree to use condom and whose female partner of childbearing potential is not using a highly effective contraceptive measure from trial start to: * six (6) months after the last dose of trial product for patients on ndec/placebo * six (6) months after the last dose of trial product for patients outside us and ca randomised to hu * twelve (12) months after the last dose of trial product for patients randomised to hu in us and ca
antiangiogenic effects of bcg on urinary concentration of angiogenic factors

Conditions: Bladder Cancer

Summary: to determine if there is an association between basic fibroblast growth factor,vascular endothelial growth factor, and interleukin levels and a patients response to bcg treatment ( as standard treatment)in the urine of patients with superficial tcc. to determine if the levels of these angiogenic factors can predict response to bcg, disease recurrence, progression risk factors.

200 patients that are candidates for intravesical bcg therapy and 20 control patients with no history of malignancy will be enrolled. the study group wol;; be asked to provide a urine sample just prior to receiving their first bcg treatment(week # 1) and just prior to receiving their last (week # 6) bcg treatment. the control patients will provide one urine sample only. samples will be analysed by enzyme-linked immunosorbant assay(elisa). clinical data will be reviewed on tumor stage and grade prior to bcg, timme to recurrence, tumor stage and grade of recurrence, time to disease progression and death, cause of death and total follow-up time.

Eligibility criteria:
inclusion criteria: 200 study group 1. must be a candidate for bcg therapy. 20 control group 1. no history of malignancy. exclusion criteria: * n/a

Keywords: antiangiogenic effects of bcg treatment and prognosis
the effects of a virtual yoga program on patients with chronic pain

Conditions: Chronic Pain

Summary: this research is being done to determine if remote yoga-based exercise can help reduce chronic pain. it will include three virtual research visits. this cohort study will include three remote research visits and an online questionnaire administration. in addition, participants will attend 8 weekly virtual yoga sessions with a daily 30-minute "homework assignment" of 30 minutes of video-guided yoga practice.


Eligibility criteria:
inclusion criteria: * chronic pain for \> 6 months' duration * on stable doses of medication prior to entering the study and agree not to change medications or dosages (or cam treatments) during the trial * have an average pain score of 4/10 or greater over the previous week * at least mild degree of sleep disturbance, defined as pittsburgh sleep quality index (psqi) score \>5 * are able to speak and understand english * have access to a computer or tablet at home and have an email address * are not currently engaged in a rigorous daily exercise routine (\>5x/week) * are willing and physically able to participate in virtual yoga-based exercise exclusion criteria: * currently under active cancer treatment (chemo, infusion, ongoing radiation) * acute osteomyelitis or acute bone disease * current diagnosis of chronic systemic inflammatory diseases including rheumatoid arthritis and lupus * present or past diagnosis of schizophrenia, delusional disorder, psychotic disorder, or dissociative disorder that would be judged to interfere with study participation * pregnancy * any clinically unstable systemic illness judged to interfere with exercise treatment * a pain condition requiring urgent surgery * an active addiction disorder, such as cocaine or iv heroin use, that would interfere with study participation * contraindications to yoga (e.g., severe back or neck injury or surgery) * regular meditation practice or other meditative practice (e.g tai-chi, meditative form of yoga or contemplative prayer) for \>20 min/week in the past 2 years * participating in any other therapeutic trial * other medical condition that would interfere with ability to exercise
intraoperative fluorescence with augmented reality

Conditions: Vascular; Lesion, Central Nervous System; Brain Tumor; Cerebral Aneurysm; Cerebral AVM

Summary: this is a study looking at a new way to evaluate vascular problems or tumors in brain surgery patients using a standard \& approved intravenous dye and augmented reality.

this is a study investigating a new technique with an approved medication (icg or indocyanine green) and using that and a near infrared mode on a standard operating room microscope to see the information provided for vascular or neoplastic (tumor related) neurosurgical problems. the technique uses the data from the microscope and using icg with augmented reality overlaying the data into the microscope view (this is the new process). the technique is called glow800.

Eligibility criteria:
inclusion criteria: * adult patients with a brain lesion requiring surgery and for whom icg videoangiography would be used exclusion criteria: * allergy to icg (indocyanine green)
brain stimulation to the hippocampus in schizophrenia

Conditions: Schizophrenia Disorders; Mental Disorder; Psychotic Disorder

Summary: schizophrenia - marked by delusions, hallucinations, and cognitive deficits - causes the most disability of any mental health condition, but existing treatments have significant side effect burden and are often ineffective. disordered neural activity in the hippocampus likely contributes to schizophrenia symptoms, but to develop better therapies we need to understand whether hippocampal activity in schizophrenia can be systematically affected by non-invasive brain stimulation techniques like transcranial magnetic stimulation (tms). this proposal will investigate the use of connectivity-guided theta burst brain stimulation to specifically target hippocampal function in schizophrenia, offering insights into fundamental hippocampal processes, schizophrenia pathophysiology, and potential avenues to use brain stimulation as a therapeutic tool in this devastating illness.


Eligibility criteria:
inclusion criteria: * men and women, ages 18 to 65 years * medically intractable epilepsy requiring phase ii monitoring (intracranial eeg arms only) * dsm-v diagnosis of schizophrenia spectrum axis i disorders including delusional disorder, brief psychotic disorder, schizophreniform disorder, schizophrenia, schizoaffective disorder (non-invasive tms-eeg arms only). * must have intellectual capacity to ensure adequate comprehension of the study and potential risks involved in order to provide informed consent * no current or history of major neurological disorders other than epilepsy. exclusion criteria: * dsm5 diagnosis of intellectual disability * significant head injury * active suicidal ideation or history of suicide attempt within the past 1 year. * medical illness affecting brain structure or function, or other uncontrolled or unstable medical condition. * pregnancy or postpartum (\<6 weeks after delivery or miscarriage) * inability to provide informed consent * active substance abuse other than alcohol or cannabis within the past 1 year * psychotic illness with a temporal relation to substance use or head injury * those with a contraindication for mris or tms (e.g. implanted metal).

Keywords: schizophrenia transcranial magnetic stimulation tms eeg
comparison of efficacy of 5% fluorocalcium phosphosilicate dentifrice and potassium nitrate dentifrice on dentinal hypersensitivity

Conditions: Dentinal Hypersensitivity

Summary: aim of this study was to assess and compare the efficacy of a dentifrice containing 5% fluoro calcium phosphosilicate and dentifrice containing potassium nitrate on dentinal hypersensitivity (dh) compared to a placebo over a period of 6 weeks.

a total of 120 subjects were divided into 3 groups randomly. group 1 was given the dentifrice containing 5% fluoro calcium phosphosilicate ,group 2 was given the dentifrice containing potassium nitrate and group 3 was given placebo. sensitivity scores (vas score) were recorded at baseline, 2 weeks, 6 weeks.

Eligibility criteria:
inclusion criteria: * the volunteers selected at baseline were in good general health and should have at least 20 natural permanent teeth and history of hypersensitivity to hot, cold, sour stimuli on at least two teeth with a vas score of ≥4. exclusion criteria: * patients with active cervical caries or deep abrasion requiring cervical filling, chipped teeth or fractured cusps, tender tooth in same quadrant as the hypersensitive teeth, subjects using any type of desensitizing paste or desensitizing therapy for last 6 months, pregnant/ lactating women or subjects with history of chronic use of anti-inflammatory and analgesic medications were excluded.

Keywords: dentinal hypersensitivity visual analogue score
hysteria evaluation of clinical hypnosis after surgical resection for crohn disease on post-operative analgesia

Conditions: Inflammatory Bowel Diseases; Anesthesia

Summary: the aim of this study will be to show a decrease in postoperative morphine consumption by the practice of perioperative self-hypnosis in patients undergoing laparoscopic ileo-caecal resection for crohn's disease


Eligibility criteria:
inclusion criteria: * being affected by a crohn's disease, reaching the small intestine (ileal or ileo-colic) and requiring ileo-caecal resection by laparoscopy * never been operated for abdominal crohn's disease exclusion criteria: * pregnant women * a history of intestinal resection for crohn's disease * emergency surgery * corticotherapy in progress * deaf patients * non-francophone patients * patients with knowledge of self-hypnosis
nipple sparing mastectomy - cosmetic outcomes

Conditions: Breast Cancer; Breast Reconstruction; Cosmesis

Summary: the purpose of this study is to observe the cosmetic outcomes, patient satisfaction, and complications after skin sparing mastectomy with preservation of the nipple areolar complex.

the outcomes will be observed in patients with both known cancer diagnosis and in those with indications for prophylactic mastectomy. the cosmetic appearance and complications will be followed through several post operative visits throughout the duration of the study. this study is conducted in conjunction with the plastic and reconstructive surgeons who will be performing the breast reconstruction procedures. patient satisfaction will be measured via survey format. in addition, local recurrence rates will be compared to patients undergoing traditional mastectomy.

Eligibility criteria:
inclusion criteria: * patients requiring mastectomy for cancer and/or prophylaxis * age greater than or equal to 18 at time of surgery * bmi less than or equal to 35 * if mastectomy is indicated for removal of breast cancer, tumor is clinically t1 or t2 exclusion criteria: * currently smoking * prior radiation to the affected breast * systemic lupus erythematosus * central tumor location and/or tumor within 2 cm of nac * paget's disease of the nipple * clinical evidence of tumor involvement in the nipple * clinical evidence of axillary nodal tumor involvement * lymphovascular invasion of the tumor on core biopsy

Keywords: breast cancer skin sparing mastectomy breast cancer prophylaxis nipple sparing mastectomy nipple areolar complex mastectomy breast reconstruction local recurrence following nipple sparing mastectomy cosmetic outcomes following nipple sparing mastectomy complications following nipple sparing mastectomy
effects of ivabradine on residual myocardial ischemia after pci

Conditions: Angina Pectoris, Stable

Summary: this is a randomized pharmacological study evaluating the effects of ivabradine in patients with residual angina after pci. the role of ivabradine in patients with angina, without systolic dysfunction, is not yet clear. the investigators performed in all patients an echostress to evaluate the effects of therapy with ivabradine after 30 days in terms of exercise tolerance and diastolic function.

background. residual angina after pci is a frequently-occurring disease. ivabradine improves symptoms but its role in patients without left-ventricular systolic dysfunction is still unclear. the aim was to quantify the effects of ivabradine in terms of mvo2 indicators and diastolic function. methods. 28 consecutive patients with residual angina after pci were randomized to ivabradine 5 mg twice/day(ig) or standard therapy(cg). all patients performed a stress echocardiography at the enrollment and after 30 days. myocardial oxygen consumption was estimated from: double product(dp); triple product(tp) integrating dp with ejection-time(et). diastolic function was evaluated determining e and a waves, e' measurements and e/e' ratio both at rest and at the peak of exercise.

Eligibility criteria:
inclusion criteria: * coronary artery disease with chronic stable angina for more than three months (canadian cardiovascular society-ccs-class i-iii); * percutaneous revascularization with stent implantation at least one; * signs/symptoms of residual ischemia; sinus rhythm; hr ≥ 70 bpm at rest; * ability to perform an echocardiogram stress test with the tilting bicycle stress test (bst); * good acoustic window; * age ≥ 18 years. exclusion criteria: * drugs intolerance or hypersensitivity * ef ≤ 40 % * nyha class iii to iv; * ccs iv * atrial fibrillation or flutter * presence of a pacemaker or implantable defibrillator * ii or iii degree av block * hr ≤ 70 bpm at rest or sick sinus syndrome * any condition that could interfere with the ability to exercise stress test like wolff- parkinson-white syndrome, left bundle branch block, left ventricular hypertrophy; * rate-corrected qt interval (qtc) greater than 500 ms or the use of drugs that prolong the qtc interval * symptomatic hypotension or uncontrolled hypertension (systolic blood pressure at rest ≥ 180 mmhg or diastolic blood pressure ≥ 100 mmhg) * severe liver disease and severe renal impairment (creatinine clearance ≤ 30 ml/min) * electrolyte disorders * uncontrolled thyroid disease * pregnancy.

Keywords: stable angina coronary artery diseases heart rate exercise tolerability diastolic function ivabradine
the natural history of congenital trigger thumbs

Conditions: Congenital Trigger Thumb; Tenosynovitis

Summary: this will be a prospective study of all children ages 0 - 5 years old at the time of entry into the study that meet the inclusion criteria who present with congenital trigger thumb. patient records will be reviewed for eligibility before obtaining parental permission. they will be enrolled in the study at their first visit and followed every year for up to 4 years or until one of the exclusion criteria are met. participating sites include the university of utah orthopaedic center, primary children's medical center and shriners hospital for children.

trigger thumb is a stenosis tenosynovitis of the flexor pollicis longus tendon of the thumb1. the eitiology of congenital trigger thumb is unclear with many authors proposing both hereditary and acquired causes2-4. surgical release of congenital trigger thumbs has been recommended as definitive treatment, though controversy exists over the natural history of congenital trigger thumbs5-8. there have been a number of studies looking at the natural history of congenital trigger thumbs with spontaneous resolution rates ranging from 0-96% over a median duration of follow up that ranged from 6 months to 48 months9-14. based on our clinical experience, the investigators do not feel that congenital trigger thumbs resolve spontaneously and that definitive treatment requires surgical release. however, the investigators need to do further scientific research into the natural history of trigger thumbs to determine how often trigger thumb resolves without needing surgical intervention.

Eligibility criteria:
inclusion criteria: * diagnosis of congenital trigger thumb based on physical exam and history, no previous treatment history (either operative or non-operative), no pain associated with the deformity, no functional disability due to the trigger thumb. exclusion criteria: * previous operative treatment for the congenital trigger thumb, deformity of the thumb that causes pain, triggering that causes secondary deformity of the thumb, and deformity that prevents normal use of the thumb and hand.

Keywords: trigger thumb flexor pollicis longus tendon of the thumb stenosis tenosynovitis
far infrared irradiation for management and treating of parkinson's disease (pd)

Conditions: Parkinson's Disease

Summary: parkinson's disease (pd) is a degenerative disorder of the central nervous system that often impairs the sufferer's motor skills and speech. this study will investigate the use of far infrared radiation to manage, control and treat pd.

parkinson's disease belongs to a group of conditions called movement disorders. it is characterized by muscle rigidity, tremor, a slowing of physical movement and, in extreme cases, a loss of physical movement. the primary symptoms are the results of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. pd is both chronic and progressive. observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells. it is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have pd.

Eligibility criteria:
inclusion criteria: * people with parkinson's disease exclusion criteria: * none

Keywords: idiopathic parkinson's disease lewy body parkinson's disease paralysis agitans parkinson's disease, idiopathic parkinson's disease, lewy body primary parkinsonism
a financial intervention (financial compass) to identify and address financial hardship among head and neck cancer patients, financial compass trial

Conditions: Head and Neck Carcinoma

Summary: this clinical trial compares the effect a financial intervention, called financial compass, to usual care in identifying and addressing financial hardship in patients with head and neck cancer. previous research has shown that head and neck cancer patients experiencing financial hardship have decreased overall and cancer specific survival. using a financial intervention, financial compass, may be more effective than usual care in identifying and addressing financial hardship in patients with head and neck cancer.

primary objectives: i. examine head and neck cancer patients' experiences with financial hardship to understand barriers across the socioeconomic spectrum and inform intervention refinement. (aim 1) ii. apply community-engaged intervention mapping to tailor the financial compass intervention to address the needs and experiences of head and neck cancer patients. (aim 2) iii. conduct a pilot randomized control trial of financial compass to assess feasibility, acceptability and preliminary efficacy among head and neck cancer patients. (aim 3) outline: aim 1: patients complete interviews on study for financial compass intervention development and refinement. aim 2: participants take part in a community advisory board and/or a health care delivery advisory board on study to discuss, develop and refine the financial compass intervention. aim 3: patients are randomized to 1 of 2 groups. group i: patients receive the financial compass intervention on study including a patient needs assessment, a tailored care pathway and weekly individualized navigation and support to access resources. group ii: patients receive usual care on study including medical consultations and supportive care. after completion of study intervention, patients are followed up at week 12.

Eligibility criteria:
inclusion criteria: * they have been diagnosed with head and neck cancer * screen positive for financial hardship on the validated comprehensive score for financial toxicity (cost) measure * are able to participate in english or spanish exclusion criteria: * adults unable to complete the process of informed consent * adults whose primary language is not english or spanish * individuals who are not yet adults (i.e., infants, children, teenagers) * unwilling or unable to follow protocol requirements